Evidence map›Paper›PMID 28369830›Full record

ReviewClinical and experimental immunology2017

Chimerism-based tolerance in organ transplantation: preclinical and clinical studies.

T Oura, A B Cosimi, T Kawai

Open access · bronzeAbstract readReview
In one paragraph

Review in Clinical and experimental immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
5.0field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 44 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Distinct roles for major and minor antigen barriers in chimerism-based tolerance under irradiation-free conditions.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2021
    Article
  7. Review
  8. Corneal xenotransplantation: Where are we standing?Progress in retinal and eye research · 2021
    Review
  9. Desensitization using imlifidase and EndoS enables chimerism induction in allosensitized recipient mice.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2020
    Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Summary of the Third International Workshop on Clinical Tolerance.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2019
    Article
  15. Review
  16. Review
  17. Immune tolerance in transplantation.Clinical and experimental immunology · 2017
    Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

T OuraDepartment of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
A B CosimiDepartment of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
T KawaiDepartment of Surgery, Center for Transplantation Sciences, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-6900-4603
Harvard University · US

Funding

Tolerance to Composite Islet-Kidney Transplants in Non-Human PrimatesU19AI102405 · NIAID · MASSACHUSETTS GENERAL HOSPITAL · PI COSIMI, A BENEDICT · 2012 to 2016
$7.7M
NIAID NIH HHS U19 AI102405
6 · The paper itself

Abstract

Induction of allograft tolerance has been considered the ultimate goal in organ transplantation. Although numerous protocols to induce allograft tolerance have been reported in mice, a chimerism-based approach through donor haematopoietic stem cell transplantation has been the only approach to date that induced allograft tolerance reproducibly following kidney transplantation in man. Renal allograft tolerance has been achieved by induction of either transient mixed chimerism or persistent full donor chimerism. Although the risk of rejection may be low in tolerance achieved via durable full donor chimerism, the development of graft-versus-host disease (GVHD) has limited the wider clinical application of this approach. In contrast, tolerance induced by transient mixed chimerism has not been associated with GVHD, but the risk of allograft rejection is more difficult to predict after the disappearance of haematopoietic chimerism. Current efforts are directed towards the development of more clinically feasible and reliable approaches to induce more durable mixed chimerism in order to widen the clinical applicability of these treatment regimens.

Indexed as

Hematopoietic Stem Cell TransplantationTransplantation ToleranceAnimalsClinical Trials as TopicDisease Models, AnimalGraft SurvivalGraft vs Host DiseaseHumansKidney TransplantationMiceTransplantation ChimeraTransplantation ConditioningTransplantation, Homologouschimerismcyclophosphamidedurable mixed chimerismfull donor chimerismGVHDhaematopoietic stem cell transplantationliving-donor kidney transplantationNHPpersistent mixed chimerismTBITITLItransient mixed chimerismtransplantation tolerance induction

Identifiers

PMID28369830
PMCPMC5508349
OpenAlexW2604757066

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.